Biodegradable implant strategies for inhibition of restenosis

Advanced Drug Delivery Reviews

Volumn 24, Issue 1, 1997, Pages 3-9

  Orloff, Lisa A ^a   Domb, Abraham J ^b   Teomim, Doron ^b   Fishbein, Ilia ^b   Golomb, Gershon ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

biodegradable drug delivery systems; heparin; polyanhydride; polyvinyl alcohol; restenosis; thrombosis

Indexed keywords

BIOMEDICAL EQUIPMENT; BLOOD VESSELS; CARDIOLOGY; DISEASES; IMPLANTS (SURGICAL); POLYSACCHARIDES; POLYVINYL ALCOHOLS;

BIODEGRADABLE DRUG DELIVERY SYSTEMS; CORONARY ARTERIES; HEPARIN; POLYANHYDRIDE; RESTENOSIS; THROMBOSIS;

DRUG THERAPY;

COLLAGEN; CYCLOSPORIN A; GELATIN; HEPARIN; OXIDIZED CELLULOSE; POLY(3 HYDROXYBUTYRIC ACID); POLY(ORTHO ESTER); POLYCAPROLACTONE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYMER; POLYVINYL ALCOHOL; UNCLASSIFIED DRUG;

ARTERY INTIMA PROLIFERATION; BIODEGRADATION; CORONARY ARTERY OBSTRUCTION; DEVICE; DRUG DELIVERY SYSTEM; EPICARDIUM; HUMAN; IMPLANT; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; REVIEW; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0031568915     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(96)00478-4     Document Type: Review

References (38)

1. [1] Holmes, D.R., Vliestra, R.E., Smith, H.C., Vetrovec, G.W, Kent, K.M., Cowley, M.J., Faxon, D.P., Gruentzig, A.R., Kelsey, S.F., Detre, K.M., Van Raden, M.J. and Mock, M.B. (1984) Restenosis after PTCA: a report from the PTCA registry of the NHLBI. Am. J. Cardiol. 53, 77C-81C.
2. [2] Nobuyoshi, M., Kimura, T., Nosaka, H., Mioka, S., Ueno, K., Yokoi, H., Hamasaki, N., Horinchi, H. and Ohishi, H. (1988) Restenosis after successful percutaneous transluminal angioplasty: serial angiographic follow-up of 229 patients. J. Am. Coll. Cardiol. 12, 616-623.
3. [3] Baumgartner, H.R. (1972) Platelet interaction with vascular structures. Thrombos. Diathes. Haemorrh. 51, 161-176.
4. [4] Wilcox, J. (1993) Molecular biology: insight into the causes and prevention of restenosis after arterial intervention. Am. J. Cardiol. 72, 88E-95E.
5. [5] Epstein, S.E., Speir, E., Unger, E.F., Guzman, R.J. and Finkel, T. (1994) The basis of molecular strategies for treating restenosis after angioplasty. J. Am. Coll. Cardiol. 23 (6), 1278-1288.
6. [6] Forrester, J.S., Fishbein, M., Helfast, R. and Fagin, J. (1991) A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J. Am. Coll. Cardiol. 17 (3), 758-769.
7. [7] Ip, J.H., Fuster, V., Badimon, L., Badimon, J. and Chesebro, J.H. (1991) The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J. Am. Coll. Cardiol. 17 (6) Suppl., 77B-88B.
8. [8] Topol, E.J. and Faxon, D.P. (1991) Symposium on restenosis: from basic studies to clinical trials. J. Am. Coll. Cardiol. 17 (6) Suppl. 1B.
9. [9] Herrmann, J.P.R., Hermans, W.R.M., Vos, J. and Serruys, P.W. (1993) Pharmacological approaches to the prevention of restenosis following angioplasty. part I. Drugs 46 (1), 18-52.
10. [10] Levy, R.J., Golomb, G., Trachy, J., Labhasetwar, V., Muller, D. and Topol, E. (1992) Strategies for treating arterial restenosis using polymeric controlled release implants. In: C. Gebelein (Ed.). Biotechnology and Bioactive Polymers, Plenum Press, New York.
11. [11] Domb, A.J. (1995) Polymeric carriers for regional drug therapy. Mol. Med. Today 3, 134-139.
12. [12] Domb, A.J. (1994) Polymers for site-specific drug delivery, In: Polymeric Site-Specific Pharmacotherapy, Domb, A J. (Ed.), Wiley. Chichester, pp. 1-26.
13. [13] Langer, R. and Peppas, N. (Eds.) (1993) Biopolymers, Vol. 107, Springer-Verlag, Berlin.
14. [14] Shalaby, S. (Ed.) (1994) Designed to Degrade Biomedical Polymers, Carl Hauser Verlag.
15. [15] Heller, J. (1980) Controlled release of biologically active compounds from bioerodible polymers. Biomaterials 1, 51-57.
16. [16] Barritt, D.W. and Jordan, S.C. (1960) Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet i, 1309-1312.
17. [17] Greenberg, B.M., Masem, M. and May, J.W. (1988) Therapeutic value of intravenous heparin in microvascular surgery: an experimental vascular thrombosis study. Plast. Reconstr. Surg. 82, 463-469.
18. [18] Rosenberg, R.D. (1977) Biological actions of heparin. Semin. Hematol. 14, 427-440.
19. [19] Psuja, P., Drouet, L. and Zawilska, K. (1987) Binding of heparin to human endothelial cell monolayer and extracellular matrix in culture. Thromb. Res. 47, 469-478.
20. [20] LeBaron, R.G., Hook, A., Esko, J.D., Gay, S. and Hook, M. (1989) Binding of heparin sulfate to type V collagen. J. Biol. Chem. 264, 7950-7956.
21. [21] Davies, J.A. and Merrys, V.C. (1982) Effect of heparin on platelet monolayer adhesion, aggregation and production of malondialdehyde. Thromb. Res. 26, 31-41.
22. [22] Clowes, A.W. and Karnovsky, M.J. (1977) Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265, 625-626.
23. [23] Clowes, A.W. and Clowes, M.M., (1986) Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration. Circ. Res. 58 (6), 839-845.
24. [24] Okada, T., Bark, D.M. and Mayberg, M.R. (1988) Local anticoagulation without systemic effect using a polymer heparin delivery system. Stroke 19 (12), 1470-1476.
25. [25] Okada, T., Bark, D.M. and Mayberg, M.R. (1989) Localized release of perivascular heparin inhibits intimal proliferation after endothelial injury without systemic anticoagulation. Neurosurgery 25 (6), 892-898.
26. [26] Mayberg, M.R. (1990) Localized release of perivascular heparin. In: D. Barrow (Ed.) Perspectives in Neurological Surgery, Quality Medical Publishing, St. Louis.
27. [27] Jones, N.S., Glenn, M.G., Orloff, L.A. and Mayberg, M.R. (1990) Prevention of microvascular thrombosis with controlled-release transmural heparin. Arch. Otolaryngol. Head Neck Surg. 116, 779-785.
28. [28] Orloff, L.A., Glenn, M.G., Domb, A.J. and Esclamado, R.A. (1995) Prevention of venous thrombosis in microvascular surgery by transmural release of heparin from a polyanhydride polymer. Surgery 117, 554-559.
29. [29] Teomim, D. (1994) Perivascular Delivery of Heparin Using Biodegradable Polymeric Films, MSc. Thesis, The Hebrew University.
30. [30] Simons, M., Edelman, E.R., Dekeyser, J.L., Langer, R. and Rosenberg, R.D. (1992) Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359, 67-70.
31. [31] Ebecke, M., Buchwald, A., Stricker, H. and Wiegand, V. (1991) In vitro assessment of polylactides as slow release drug carriers. Circulation 84 (Suppl.), 11-72.
32. [32] Villa, A.E., Guzman, L.A., Poptic, E.J., Labhasetwar, V., D'Souza, S., Farrell, C.E., Plow, E.F., Levy, R., DiCorleto, P.E. and Topol, E.J. (1995) Effect of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury, Circ. Res. 76, 505-513.
33. [33] Bier, J.D., Zalesky, P., Sasken, H. and Williams, D.O. (1991) A new bioabsorbable intravascular stent: in vitro assessment of hemodynamic and morphometric characteristics. Circulation 84 (Suppl.), 11-197.
34. [34] Radovsky, A.S., Van Vleet, J.F., Stokes, K.B. and Tacker, W.C. (1988) Paired comparison of steroid eluting and nonsteroid endocardial pacemaking leads in dogs: electrical performance and morphological changes. PACE 11, 1085-1094.
35. [35] Sintov, A., Scott, W., Dick, M. and Levy, R.J. (1988) Cardiac controlled release for arrhythmia therapy: lidocaine-polyurethane studies. J. Control. Release 8, 157-165.
36. [36] Olanoff, L.S., Anderson, J.M. and Jones, R.D. (1979) Sustained release of gentamycin from prosthetic valves. Trans. Am. Soc. Artif. Intern. Organs 25, 334-338.
37. [37] Levy, R.J., Wolfrum, J., Schoen, F.J., Hawley, M.A., Lund, S.A. and Langer, R. (1985) Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate. Science 228, 190-192.
38. [38] Bolling, S.F., Lin, H., Annesley, T.M., Boyd, J.A., Gallagher, K.P. and Levy, R.J. (1991) Local cyclosporine immunotherapy of heart transplants in rats enhances survival. J. Heart Lung Transplant. 10, 577-583.